Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 32c ; Offers Guidance

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($1.06), $0.32 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $176 million versus the consensus estimate of $166.03 million.

FY 2026 Outlook:-

Revenue between $680 million to $700 million vs consensus $678 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• General Dynamics wins $249m in US military contracts
• Stardust Solar plans $641K convertible debenture private placement